Skip to content
Screener

BioMarin Pharmaceuticals BMRN Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$555K-98.3%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$12.35B+12.2%
Enterprise value$15.66B+50.7%
P/E34.3×-37.0×
P/S3.6×0.0×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Other long-term liabilities6,6675,537
Net cash provided by operating activities388,760359,665
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment(49,739)(33,869)
Maturities and sales of investments767,277195,738
Purchases of investments(25,792)(202,433)
Purchase of intangible assets(5,433)(266)
Acquisition of Amicus, net of cash acquired(5,067,630)

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's payments to acquire property, plant, and equipment?
BioMarin Pharmaceuticals (BMRN) reported payments to acquire property, plant, and equipment of $28.82M in Q2 2026.
How has BioMarin Pharmaceuticals's payments to acquire property, plant, and equipment changed year-over-year?
BioMarin Pharmaceuticals's payments to acquire property, plant, and equipment increased by 68.5% year-over-year, from $17.1M to $28.82M.
What is the long-term trend for BioMarin Pharmaceuticals's payments to acquire property, plant, and equipment?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's payments to acquire property, plant, and equipment has grown at a 1.9% compound annual growth rate (CAGR), from $95.58M to $103.04M.
What does payments to acquire property, plant, and equipment mean?
Payments to Acquire Property, Plant, and Equipment

Ask your AI about BioMarin Pharmaceuticals's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude